Alembic Pharmaceuticals completes USFDA RRA for its bioequivalence facility
News

Alembic Pharmaceuticals completes USFDA RRA for its bioequivalence facility

The RRA was conducted from 22nd August, 2022 to 26th August, 2022.

  • By IPP Bureau | August 29, 2022

Alembic Pharmaceuticals Limited has successfully completed the US Food and Drug Administration (USFDA) Remote Regulatory Assessment (RRA) for its Bioequivalence Facility, Bio-analytical division, located at Vadodara, without any observations.

The RRA was conducted from 22nd August, 2022 to 26th August, 2022.

Other Related stories

Startup

Digitization

India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
Sanjay Vyas President and Managing Director, Parexel India And Global SBU Head- Safety services & Logistics, Parexel International